Patents by Inventor Adrien Weingartner

Adrien Weingartner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220290144
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 15, 2022
    Inventors: Sibylle Dames, Steffen Schubert, Stephan Tenbaum, Christian Frauendorf, Lucas Bethge, Judith Hauptmann, Adrien Weingartner, David Anthony Rider
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL
    Publication number: 20220017899
    Abstract: The invention relates to nucleic acid products that interfere with complement component C3 gene expression or inhibit its expression. The nucleic acids are preferably for use as treatment, prevention or reduction of risk of suffering from complement component C3 associated diseases, disorders or syndromes, particularly C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), Lupus nephritis, IgA nephropathy (IgA N), Cold Agglutinin Disease (CAD), Myasthenia gravis (MG), and Primary Membranous Nephropathy.
    Type: Application
    Filed: November 22, 2019
    Publication date: January 20, 2022
    Inventors: Verena Aumiller, Sibylle Dames, Steffen Schubert, Judith Hauptmann, Christian Frauendorf, Marie Wikstrom Lindholm, Adrien Weingartner, Lucas Bethge